Literature DB >> 1881260

Reaction of gadolinium chelates with endogenously available ions.

M F Tweedle1, J J Hagan, K Kumar, S Mantha, C A Chang.   

Abstract

The extent of reaction of 153Gd-radiolabeled Gd(L) chelates with 25 mM CO23- (25 mF), PO34-, Zn2+ and Cu2+ at pH 7 was determined for L = EDTA, DTPA, DOTA, HP-DO3A, and DO3A. Gd(EDTA)- and Gd(DTPA)2- reacted (greater than 20% in 10 min) with Cu2+ and Zn2+ in the presence of PO34-. These double replacement reactions yielded precipitated GdPO4 and chelated Cu(L). Gd(HP-DO3A), Gd(DO3A) and Gd(DOTA)- were inert to reaction with all four ions at room temperature (less than or equal to 1% reaction detected). The thermodynamic binding constants of the ligands for Gd3+ and Cu2+ were found to be equal (10(20) M-1) for DO3A, while DOTA and HP-DO3A favored Gd3+ over Cu2+ by greater than or equal to 10(2) M-1. The low order of reactivity of Gd(DOTA)- and Gd(HP-DO3A) was anticipated by the binding constants, but the lack of reactivity of Gd(DO3A) is attributed to kinetic inertia. This latter property, desirable in MRI contrast agents, is promoted by the conformational stability of the tetraazacyclododecane macrocycle, which forms the backbone of the ligand. It is concluded that this class of chelates is exceptionally inert in solutions of endogenously available ions, and that thermodynamics alone is an insufficient predictor of the reactivity of the highly inert Gd complexes based on the tetraazamacrocycle.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881260     DOI: 10.1016/0730-725x(91)90429-p

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  27 in total

1.  Imaging human pancreatic cancer xenografts by targeting mutant KRAS2 mRNA with [(111)In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles.

Authors:  Nariman V Amirkhanov; Kaijun Zhang; Mohan R Aruva; Mathew L Thakur; Eric Wickstrom
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

2.  Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.

Authors:  Alessandra Splendiani; Marco Perri; Claudia Marsecano; Valentina Vellucci; Giulia Michelini; Antonio Barile; Ernesto Di Cesare
Journal:  Radiol Med       Date:  2017-09-27       Impact factor: 3.469

3.  Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats.

Authors:  Xueming Wu; Yuda Zong; Zhen Ye; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2010-07       Impact factor: 4.200

Review 4.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

5.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.

Authors:  Josef A Schroeder; Christian Weingart; Brigitte Coras; Ingrid Hausser; Stephan Reinhold; Matthias Mack; Volker Seybold; Thomas Vogt; Bernhard Banas; Ferdinand Hofstaedter; Bernhard K Krämer
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

6.  Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA).

Authors:  P Brugières; A Gaston; H R Degryse; P M Parizel; A M de Schepper; I Berry; C Manelfe; F Le Bras; C Marsault; W Wichmann
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

7.  The synthesis and in vitro testing of a zinc-activated MRI contrast agent.

Authors:  Jody L Major; Giacomo Parigi; Claudio Luchinat; Thomas J Meade
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-27       Impact factor: 11.205

Review 8.  Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.

Authors:  Hale Ersoy; Frank J Rybicki
Journal:  J Magn Reson Imaging       Date:  2007-11       Impact factor: 4.813

Review 9.  Pathophysiology of gadolinium-associated systemic fibrosis.

Authors:  Brent Wagner; Viktor Drel; Yves Gorin
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-04

10.  Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance.

Authors:  Antonella Meloni; Domenico Montanaro; Daniele De Marchi; Mariachiara Resta; Petra Keilberg; Laura Pistoia; Vincenzo Positano; Anna Spasiano; Tommaso Casini; Caterina Cinzia De Bari; Sara De Cori; Alessia Pepe
Journal:  Clin Neuroradiol       Date:  2020-03-17       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.